The stock of Allogene Therapeutics Inc (ALLO) has gone down by -10.00% for the week, with a -13.60% drop in the past month and a -46.93% drop in the past quarter. The volatility ratio for the week is 7.81%, and the volatility levels for the past 30 days are 7.57% for ALLO. The simple moving average for the last 20 days is -10.80% for ALLO stock, with a simple moving average of -35.04% for the last 200 days.
Is It Worth Investing in Allogene Therapeutics Inc (NASDAQ: ALLO) Right Now?
The stock has a 36-month beta value of 0.85. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALLO is 136.69M, and at present, short sellers hold a 31.66% of that float. On July 03, 2024, the average trading volume of ALLO was 2.66M shares.
ALLO) stock’s latest price update
Allogene Therapeutics Inc (NASDAQ: ALLO) has seen a decline in its stock price by -7.30 in relation to its previous close of 2.33. However, the company has experienced a -10.00% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-07-01 that SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) — Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that Rocky Mountain Cancer Centers (RMCC), part of the US Oncology Network and Sarah Cannon Research Institute (SCRI); Astera Cancer Care (ACC), a multi-specialty community oncology practice and part of the OneOncology network; and Norton Cancer Institute, are open for enrollment in the pivotal Phase 2 ALPHA3 trial.
Analysts’ Opinion of ALLO
Many brokerage firms have already submitted their reports for ALLO stocks, with Piper Sandler repeating the rating for ALLO by listing it as a “Overweight.” The predicted price for ALLO in the upcoming period, according to Piper Sandler is $11 based on the research report published on May 31, 2024 of the current year 2024.
ALLO Trading at -19.19% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.30% of loss for the given period.
Volatility was left at 7.57%, however, over the last 30 days, the volatility rate increased by 7.81%, as shares sank -13.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.75% lower at present.
During the last 5 trading sessions, ALLO fell by -10.00%, which changed the moving average for the period of 200-days by -45.32% in comparison to the 20-day moving average, which settled at $2.40. In addition, Allogene Therapeutics Inc saw -32.71% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from MESSEMER DEBORAH M., who sale 18,641 shares at the price of $2.28 back on Jun 18 ’24. After this action, MESSEMER DEBORAH M. now owns 166,765 shares of Allogene Therapeutics Inc, valued at $42,488 using the latest closing price.
Humer Franz B, the Director of Allogene Therapeutics Inc, sale 11,200 shares at $2.34 during a trade that took place back on May 30 ’24, which means that Humer Franz B is holding 255,253 shares at $26,181 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- -2191.24 for the present operating margin
- -503.47 for the gross margin
The net margin for Allogene Therapeutics Inc stands at -2231.4. The total capital return value is set at -0.51. Equity return is now at value -55.06, with -43.52 for asset returns.
Based on Allogene Therapeutics Inc (ALLO), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -2.37. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -778.31.
Currently, EBITDA for the company is -287.05 million with net debt to EBITDA at -0.17. When we switch over and look at the enterprise to sales, we see a ratio of 3813.7. The receivables turnover for the company is 0.08for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.80.
Conclusion
To sum up, Allogene Therapeutics Inc (ALLO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
